Systemic Lupus ErythematosusCOLUPUSNCT06551389
Follow-up of the Systemic Lupus Erythematosus Cohort as Part of the Multidisciplinary Consultation at Brest CHRU
An observational study of Systemic Lupus Erythematosus, run by University Hospital, Brest at 1 site in France.
Trial summary
Systemic lupus erythematosus is a complex systemicautoimmune disease that can affect most organs of the human body. Although they are many recommendations on the diagnosis and managment of SLE, diagnosis and therapeutic managment is still challenging. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Systemic Lupus Erythematosus
- How many people
- 300 participants
- Where
- 1 siteFrance
- Study dates
- 13 Oct 2020to Apr 2035
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients of the systemic lupus erythematous's multidisciplinary consultation at Brest CHRU
Who may be able to join
- Any patient over 18 years old of the multidisciplinary consultation
Who cannot join
- Opposition of patient
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Sandrine JOUSSE-JOULIN, Rheumatologist contact
France1 site, 1 recruiting
- Recruiting
CHRU de Brest
Brest, 29609
Sandrine JOUSSE-JOULIN, sandrine.jousse@chu-brest.fr
About this study
Systemic lupus erythematosus is a complex systemicautoimmune disease that can affect most organs of the human body.
Although they are many recommendations on the diagnosis and managment of SLE, diagnosis and therapeutic managment is still challenging.
Read more
A pluridisciplinary consultation grouping rheumatologist, nephrologist, dermatologist, gynecologist, internist and immunologists has been set up in 2009 at the university hospital of Brest.
The investigators would like to identify in a longitudinal cohort the occurrence of the different clinico-biological and immunological patterns of systemic lupus erythematosus patients during our multidisciplinary consultation.
It is now crucial to organize a standardized data collection of these patients in order to evaluate our pratices, to be able to study the epidemiology of SLE in our city, and to promote this initiative at national and international level.
- Conditions
- Systemic Lupus Erythematosus
- Keywords
- autoimmune diseases, joint diseases, cutaneous systemic diseases, musculoskeletal diseases, arthritis, rheumatoid, rheumatic diseases, connectivite tissue diseases, immune system diseases
- Medical subject headings
- Lupus Erythematosus, Systemic, Autoimmune Diseases, Joint Diseases, Musculoskeletal Diseases, Arthritis, Rheumatic Diseases, Immune System Diseases
What is being measured
The primary outcome is the main question the study is designed to answer.
Cohort data
Prevalence and incidence of the clinico-biological and immunological patterns in a longitudinal cohort present in the standardized collection book including evaluation of différents criteria aspects : SLICC criteria
Measured: one year
Cohort data
Prevalence and incidence of the clinico-biological and immunological patterns in a longitudinal cohort present in the standardized collection book including evaluation of différents criteria aspects : SLEDAI score
Measured: one year
Cohort data
Prevalence and incidence of the clinico-biological and immunological patterns in a longitudinal cohort present in the standardized collection book including evaluation of différents criteria aspects : SDI score
Measured: one year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Aug 2024
- Study start13 Oct 2020
- Primary completionApr 2035 (estimated)
- Study completionApr 2035 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Systemic Lupus ErythematosusStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Brest
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06551389
- Sponsor's protocol ID
- COLUPUS (2017.CE.10)
- Acronym
- COLUPUS
- Status last verified
- Jun 2026
- First submitted
- 20 Jun 2019
- Last updated
- 25 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No